PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 105 participants.

Also called NCT03970538

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 105 participants (enrolled count) (from the registry)
Sponsor
LimFlow, Inc. (from the registry)
Registry
  • NCT NCT03970538
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03970538. Allocation not applicable; no masking; primary purpose treatment. Start 2019-12-06 (actual); primary completion 2022-09-09 (actual). Results posted on 2024-02-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
Acronym
PROMISE
Condition
Critical Limb Ischemia
Condition
Critical Lower Limb Ischemia
Condition
Peripheral Artery Disease
Condition
Peripheral Arterial Disease
Condition
Chronic Limb-Threatening Ischemia
Condition
Arterial Occlusive Diseases
Condition
Arterial Occlusion
Condition
Arterial Disease
Condition
Peripheral Artery Occlusion
Condition
Peripheral Vascular Disease
Condition
Peripheral Ischemia
Condition
Vascular Diseases
Intervention (Device)
LimFlow System
Lead sponsor
LimFlow, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03970538
Content hash
0e44474daa5d4a78f7c88689b2edbc51a79b056db3535bb4f5b3747ffe8edcfe